MARKET

HUMA

HUMA

Humacyte Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

10.39
-0.55
-5.03%
After Hours: 10.00 -0.39 -3.75% 18:05 12/03 EST
OPEN
10.94
PREV CLOSE
10.94
HIGH
10.94
LOW
9.87
VOLUME
531.70K
TURNOVER
--
52 WEEK HIGH
17.45
52 WEEK LOW
8.61
MARKET CAP
1.07B
P/E (TTM)
-5.9243
1D
5D
1M
3M
1Y
5Y
BRIEF-Humacyte Presents Preclinical Results Of Small-Diameter HAV™
reuters.com · 11/16 12:58
Humacyte Presents Preclinical Results Of Small-Diameter HAV For Use As A BTT Shunt In Pediatric Heart Disease At American Heart Association's Scientific Sessions 2021
Humacyte, Inc. (NASDAQ:HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced positive results from a preclinical study
Benzinga · 11/16 12:39
Humacyte Presents Preclinical Results of Small-Diameter HAV™ for Use as a BTT Shunt in Pediatric Heart Disease at American Heart Association’s Scientific Sessions 2021
-- Patency and host cell remodeling of the HAV were observed in all study implants – -- Preclinical study is one component of Humacyte’s expansion of the...
Globe Newswire · 11/16 12:30
Humacyte Highlights Presentation Of 12-Month Data From Human Acellular Vessel Produced Using Commercial-Scale Manufacturing System
– Performance of HAVs produced in the LUNA200™ commercial-scale system demonstrated efficacy that is similar to prior HAV performance in dialysis access trials – – 83% secondary patency
Benzinga · 11/15 14:34
Humacyte Presents New 12-Month Data from HAVs™ Produced Using Commercial-Scale Manufacturing System
– Performance of HAVs produced in the LUNA200™ commercial-scale system demonstrated efficacy that is similar to prior HAV performance in dialysis access trials – – 83% secondary patency observed at 12 months post-implantation – – Data presented today in ke...
GlobeNewswire · 11/15 14:30
Humacyte reports Q3 results
Humacyte (NASDAQ:HUMA): Q3 GAAP EPS of -$0.72. Revenue of $0.24M (-73.6% Y/Y) Press Release
Seekingalpha · 11/12 12:53
Humacyte Q3 EPS $(0.72) Up From $(3.07) YoY, Grant Sales $241.00K Down From $914.00K YoY
Humacyte (NASDAQ:HUMA) reported quarterly losses of $(0.72) per share. This is a 76.55 percent increase over losses of $(3.07) per share from the same period last year. The company reported $241.00 thousand in sales
Benzinga · 11/12 12:39
Humacyte's Q3 Loss Narrows, Revenue Declines
MT Newswires · 11/12 09:10
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of HUMA. Analyze the recent business situations of Humacyte Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

33.33%Strong Buy
66.67%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average HUMA stock price target is 17.83 with a high estimate of 20.00 and a low estimate of 16.00.
High20.00
Average17.83
Low16.00
Current 10.39
EPS
Actual
Estimate
-0.69-0.47-0.24-0.02
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 32
Institutional Holdings: 7.20M
% Owned: 6.99%
Shares Outstanding: 103.00M
TypeInstitutionsShares
Increased
7
86.90K
New
20
6.53M
Decreased
1
1.66K
Sold Out
16
2.45M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
About HUMA
Humacyte, Inc. (Humacyte), formerly Alpha Healthcare Acquisition Corp., is a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale. The Company uses its technology platform to engineer and manufacture human acellular vessels (HAVs). The HAVs are designed to be implanted into any patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio (or cabinet) of HAVs with varying diameters and lengths. The HAV cabinet offers treatment solution in various clinical areas within vascular repair, reconstruction and replacement market, including trauma, AV access for hemodialysis, peripheral arterial disease (PAD), and coronary artery bypass grafting (CABG). In addition, the Company develops HAVs for pediatric heart surgery and the delivery of cellular therapies, including pancreatic islet cell transplantation to treat Type 1 diabetes.

Webull offers kinds of Humacyte Inc stock information, including NASDAQ:HUMA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HUMA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HUMA stock methods without spending real money on the virtual paper trading platform.